Search Results
Hanna Karhapää
Hanna Karhapää
Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Karhapää in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Karhapää in
Google Scholar
PubMed
Siru Mäkelä
Siru Mäkelä
Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Siru Mäkelä in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Siru Mäkelä in
Google Scholar
PubMed
Hanna Laurén
Hanna Laurén
Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Laurén in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Laurén in
Google Scholar
PubMed
Marjut Jaakkola
Marjut Jaakkola
Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed
Camilla Schalin-Jäntti
Camilla Schalin-Jäntti
Medical Faculty, University of Helsinki, Helsinki, Finland
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Micaela Hernberg
Micaela Hernberg
Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Micaela Hernberg in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Micaela Hernberg in
Google Scholar
PubMed
multidisciplinary meeting before treatment initiation. We collected the following data from the patient records: patient age at treatment initiation, sex, and ECOG performance status. Furthermore, we listed the characteristics of metastatic disease, including
Mark J C van Treijen
Mark J C van Treijen
Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by Mark J C van Treijen in
Google Scholar
PubMed
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by Mark J C van Treijen in
Google Scholar
PubMed
Catharina M Korse
Catharina M Korse
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Catharina M Korse in
Google Scholar
PubMed
Department of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Catharina M Korse in
Google Scholar
PubMed
Wieke H Verbeek
Wieke H Verbeek
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Gastroenterology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Wieke H Verbeek in
Google Scholar
PubMed
Department of Gastroenterology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Wieke H Verbeek in
Google Scholar
PubMed
Margot E T Tesselaar
Margot E T Tesselaar
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Margot E T Tesselaar in
Google Scholar
PubMed
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Margot E T Tesselaar in
Google Scholar
PubMed
Gerlof D Valk
Gerlof D Valk
Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by Gerlof D Valk in
Google Scholar
PubMed
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by Gerlof D Valk in
Google Scholar
PubMed
received sunitinib (2%). Treatment response was defined as PFS ≥ 12 months after treatment initiation. A total of 34 patients showed response to treatment (69%). The median TTP after the start of treatment was 20 months (2–66 months). Significant
